RibFix Advantage™ Post-Market Follow-Up

NCT05179005 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 1

Last updated 2024-01-29

No results posted yet for this study

Summary

To confirm safety, performance, and clinical benefits for the use of RibFix Advantage™ in the fixation, stabilization, and fusion of rib fractures and osteotomies of normal and osteoporotic bone

Conditions

  • Rib Fractures

Interventions

DEVICE

RibFix Advantage

Intrathoracic rib fracture stabilization

Sponsors & Collaborators

  • Zimmer Biomet

    lead INDUSTRY

Principal Investigators

  • Christopher W Towe, MD · UH Seidman Cancer Center

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-04-20
Primary Completion
2023-12-31
Completion
2023-12-31
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05179005 on ClinicalTrials.gov